vs
Absci Corp（ABSI）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是Absci Corp的54.7倍（$35.5M vs $650.0K），RECURSION PHARMACEUTICALS, INC.净利率更高（-304.2% vs -4548.0%，领先4243.8%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs -2.3%），Absci Corp自由现金流更多（$-29.3M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs -6.5%）
Absci Corp是一家结合合成生物学与人工智能技术的生物技术企业，为全球制药及生物制药合作伙伴提供集成式蛋白质工程解决方案，加速抗体、治疗性蛋白等新型生物候选药物的研发，助力满足未被覆盖的临床医疗需求。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
ABSI vs RXRX — 直观对比
营收规模更大
RXRX
是对方的54.7倍
$650.0K
营收增速更快
RXRX
高出684.0%
-2.3%
净利率更高
RXRX
高出4243.8%
-4548.0%
自由现金流更多
ABSI
多$18.0M
$-47.3M
两年增速更快
RXRX
近两年复合增速
-6.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $650.0K | $35.5M |
| 净利润 | $-29.6M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | -4775.5% | -304.8% |
| 净利率 | -4548.0% | -304.2% |
| 营收同比 | -2.3% | 681.7% |
| 净利润同比 | -2.0% | 39.6% |
| 每股收益（稀释后） | $-0.19 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABSIRXRX
| Q4 25 | $650.0K | $35.5M | ||
| Q3 25 | — | $5.2M | ||
| Q2 25 | $593.0K | $19.2M | ||
| Q1 25 | $1.2M | $14.7M | ||
| Q4 24 | $665.0K | $4.5M | ||
| Q3 24 | $1.7M | $26.1M | ||
| Q2 24 | $1.3M | $14.4M | ||
| Q1 24 | $898.0K | $13.8M |
净利润ABSIRXRX
| Q4 25 | $-29.6M | $-108.1M | ||
| Q3 25 | — | $-162.3M | ||
| Q2 25 | $-30.6M | $-171.9M | ||
| Q1 25 | $-26.3M | $-202.5M | ||
| Q4 24 | $-29.0M | $-178.9M | ||
| Q3 24 | $-27.4M | $-95.8M | ||
| Q2 24 | $-24.8M | $-97.5M | ||
| Q1 24 | $-22.0M | $-91.4M |
毛利率ABSIRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率ABSIRXRX
| Q4 25 | -4775.5% | -304.8% | ||
| Q3 25 | — | -3327.6% | ||
| Q2 25 | -5293.9% | -916.8% | ||
| Q1 25 | -2351.9% | -1297.9% | ||
| Q4 24 | -4477.3% | -4042.4% | ||
| Q3 24 | -1698.7% | -377.1% | ||
| Q2 24 | -2104.0% | -697.4% | ||
| Q1 24 | -2616.7% | -698.4% |
净利率ABSIRXRX
| Q4 25 | -4548.0% | -304.2% | ||
| Q3 25 | — | -3135.3% | ||
| Q2 25 | -5155.0% | -894.2% | ||
| Q1 25 | -2234.6% | -1373.3% | ||
| Q4 24 | -4358.3% | -3935.5% | ||
| Q3 24 | -1610.7% | -367.5% | ||
| Q2 24 | -1948.8% | -676.6% | ||
| Q1 24 | -2447.1% | -662.4% |
每股收益（稀释后）ABSIRXRX
| Q4 25 | $-0.19 | $-0.17 | ||
| Q3 25 | — | $-0.36 | ||
| Q2 25 | $-0.24 | $-0.41 | ||
| Q1 25 | $-0.21 | $-0.50 | ||
| Q4 24 | $-0.26 | $-0.56 | ||
| Q3 24 | $-0.24 | $-0.34 | ||
| Q2 24 | $-0.22 | $-0.40 | ||
| Q1 24 | $-0.22 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $144.3M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $189.4M | $1.1B |
| 总资产 | $216.3M | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资ABSIRXRX
| Q4 25 | $144.3M | $743.3M | ||
| Q3 25 | — | $659.8M | ||
| Q2 25 | $38.0M | $525.1M | ||
| Q1 25 | $47.0M | $500.5M | ||
| Q4 24 | $112.4M | $594.4M | ||
| Q3 24 | $38.2M | $427.6M | ||
| Q2 24 | $42.9M | $474.3M | ||
| Q1 24 | $58.8M | $296.3M |
总债务ABSIRXRX
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | $4.0M | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益ABSIRXRX
| Q4 25 | $189.4M | $1.1B | ||
| Q3 25 | — | $1.0B | ||
| Q2 25 | $173.4M | $919.1M | ||
| Q1 25 | $198.8M | $933.9M | ||
| Q4 24 | $179.1M | $1.0B | ||
| Q3 24 | $201.3M | $524.6M | ||
| Q2 24 | $221.5M | $584.4M | ||
| Q1 24 | $240.1M | $401.2M |
总资产ABSIRXRX
| Q4 25 | $216.3M | $1.5B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | $209.9M | $1.3B | ||
| Q1 25 | $232.4M | $1.3B | ||
| Q4 24 | $213.6M | $1.4B | ||
| Q3 24 | $235.2M | $726.5M | ||
| Q2 24 | $255.5M | $775.9M | ||
| Q1 24 | $274.9M | $557.8M |
负债/权益比ABSIRXRX
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | 0.02× | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-29.2M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $-29.3M | $-47.3M |
| 自由现金流率自由现金流/营收 | -4505.4% | -133.1% |
| 资本支出强度资本支出/营收 | 15.8% | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-85.2M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流ABSIRXRX
| Q4 25 | $-29.2M | $-46.1M | ||
| Q3 25 | — | $-117.4M | ||
| Q2 25 | $-16.9M | $-76.4M | ||
| Q1 25 | $-21.8M | $-132.0M | ||
| Q4 24 | $-17.0M | $-115.4M | ||
| Q3 24 | $-20.7M | $-59.2M | ||
| Q2 24 | $-16.8M | $-82.2M | ||
| Q1 24 | $-17.9M | $-102.3M |
自由现金流ABSIRXRX
| Q4 25 | $-29.3M | $-47.3M | ||
| Q3 25 | — | $-117.6M | ||
| Q2 25 | $-17.1M | $-79.6M | ||
| Q1 25 | $-21.9M | $-133.8M | ||
| Q4 24 | $-17.0M | $-116.7M | ||
| Q3 24 | $-20.8M | $-63.8M | ||
| Q2 24 | $-17.2M | $-83.4M | ||
| Q1 24 | — | $-109.0M |
自由现金流率ABSIRXRX
| Q4 25 | -4505.4% | -133.1% | ||
| Q3 25 | — | -2272.5% | ||
| Q2 25 | -2883.0% | -413.9% | ||
| Q1 25 | -1854.5% | -907.4% | ||
| Q4 24 | -2554.4% | -2567.7% | ||
| Q3 24 | -1221.6% | -244.6% | ||
| Q2 24 | -1352.4% | -578.5% | ||
| Q1 24 | — | -789.9% |
资本支出强度ABSIRXRX
| Q4 25 | 15.8% | 3.5% | ||
| Q3 25 | — | 4.7% | ||
| Q2 25 | 37.6% | 16.4% | ||
| Q1 25 | 2.1% | 12.4% | ||
| Q4 24 | 3.5% | 28.6% | ||
| Q3 24 | 2.8% | 17.5% | ||
| Q2 24 | 26.2% | 8.2% | ||
| Q1 24 | 0.0% | 48.2% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
